Bulkamid Treatment of Stress Incontinence in Women With Urinary Stress Incontinence and Not Suitable to TVT-procedure

NCT ID: NCT00984958

Last Updated: 2019-08-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

50 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-10-31

Study Completion Date

2016-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this prospective, randomized study of Bulkamid treatment is to investigate the efficacy of Bulkamid treatment in women with urinary stress incontinence not suitable to TVT-procedure because of suspected ISD.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this prospective, randomized study is to investigate the effect of Bulkamid injection for women with urinary stress incontinence and not suitable to TVT-procedure because of suspected ISD and compare this treatment with no or traditional treatment. The primary endpoint for efficacy will be reduction of leakage during pad-test at 2 months compared with pad- test before injection.

Secondary endpoints will be patient satisfaction measured at both 2 and 12 months using a questionnaire and the number of side effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Urinary Stress Incontinence Treatment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Group 1 will get treatment and Group 2 will have no treatment for 2 month
Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bulkamid

Injection with Bulkamid

Group Type OTHER

Bulkamid

Intervention Type DEVICE

injection of Bulkamid in the urethra

expectance

The expectance arm will after 2 month have the same treatment as the treatment arm

Group Type OTHER

Bulkamid expectation

Intervention Type DEVICE

expectance

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bulkamid

injection of Bulkamid in the urethra

Intervention Type DEVICE

Bulkamid expectation

expectance

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

after 2 month the patient can be treated

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Ability to understand the information and to give informed consent.

* At least 50 years of age
* History of urinary leakage during low grade physical activity. A woman with genuine stress incontinence has urinary incontinence during running or jumping. Women with suspected ISD have incontinence at much lower grade of physical activity such as slow walking or standing up and just coughing. Walking, standing up from a chair, and coughing are regarded as low grade of physical activity.
* A positive pad-test (after coughing 10 times) with increase of minimum of 10 grams of urine with 300 ml in the bladder or a 24 h pad-test of more than 100 mg of urine
* No hypermobility of the urethra during cough test.
* Low pressure of the urethra (optional?)
* With a of average miction volume of minimum 150 ml and at least one volume of more than 250

Exclusion Criteria

* Women with hypermobility of the urethra during coughing and positive Bonney's test
* Women suitable for a TVT procedure.
* Positive urinary culture
* Urge incontinence
Minimum Eligible Age

50 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Skaraborg Hospital

OTHER_GOV

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Per-Goran Larsson

professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

P-G Larsson, professor

Role: PRINCIPAL_INVESTIGATOR

Departm Ob/Gyn Kärnsjukhuset, 541 85 SKövde, Sweden

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Deprtm Ob/Gyn

Skövde, , Sweden

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Sweden

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Bulkamid ISD2009 04

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.